Technetium 99m-pyridoxylideneglutamate: a new hepatobiliary radiopharmaceutical. I. Experimental aspects.
J Nucl Med
; 16(8): 720-7, 1975 Aug.
Article
de En
| MEDLINE
| ID: mdl-240915
ABSTRACT
The labeling of pyridoxal and the pyridoxylidene derivative of glutamic acid with 99mTc has been achieved by a simple autoclaving procedure. Technetium-99-m-pyridoxylideneglutamate (99mTc-PG) shows marked biliary excretion with accumulation of radioactivity in the gallbladder and intestines of experimental animals. This compound has been extensively investigated with a view to its application in the diagnosis of biliary disorders in man by scintigraphy. Both scintigraphic and quantitative distribution studies showed that 99mTc-PG passed rapidly through the mouse liver with progressive accumulation in the gallbladder, allowing visualization of this organ within 10 min of injection. In 30 min over 40% of the injected dose was excreted into the intestine with an equivalent amount appearing in the urine; however, renal activity remained low. Scintigraphic studies in dogs showed results similar to those obtained in mice. Studies of the toxicity in three animal species indicated a wide margin of safety for 99mTc-PG in the dose proposed for diagnostic purposes in humans.
Recherche sur Google
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Pyridoxal
/
Voies biliaires
/
Scintigraphie
/
Technétium
/
Glutamates
/
Foie
Limites:
Animals
Langue:
En
Journal:
J Nucl Med
Année:
1975
Type de document:
Article